stdClass Object
(
[id] => 10147
[paper_index] => 202302-02-012495
[title] => A COMPREHENSIVE REVIEW ARTICLE ON FINERENONE
[description] =>
[author] => Dr.Sanjay Prajapati, Dr. Pratik Prajapati, Kajal Gondaliya
[googlescholar] => https://scholar.google.co.in/scholar?cluster=8282749593449906904&hl=en&as_sdt=0,5
[doi] =>
[year] => 2023
[month] => February
[volume] => 8
[issue] => 2
[file] => 416pm_36.EPRA JOURNALS 12495.pdf
[abstract] => Finerenone is a Novel selective Non-steroidal Mineralocorticoids Receptor Antagonist. Finerenone is indicated for the treatment of Chronic kidney disease (stage 3 and stage 4) associated with type 2 diabetes in adults. Finerenone blocks the MR receptor so that the progression of chronic kidney disease is control. Finerenone belongs to the BCS class-II, low solubility and low half life and bioavailbility.
[keywords] => Finerenone, Chronic kidney disease, Solubility, BCS Class.
[doj] => 2023-02-25
[hit] => 3447
[status] => y
[award_status] => P
[orderr] => 36
[journal_id] => 2
[googlesearch_link] => https://www.google.com/search?q=A+COMPREHENSIVE+REVIEW+ARTICLE+ON+FINERENONE+Dr.Sanjay+Prajapati%2C+Dr.+Pratik+Prajapati%2C+Kajal+Gondaliya&rlz=1C1CHBD_enIN959IN959&sourceid=chrome&ie=UTF-8
[edit_on] =>
[is_status] => 1
[journalname] => EPRA International Journal of Research & Development (IJRD)
[short_code] => IJSR
[eissn] => 2455-7838 (Online)
[pissn] => - -
[home_page_wrapper] => images/products_image/2-n.png
)
Warning: file_get_contents(https://eprajournals.com/files_list/416pm_36.EPRA JOURNALS 12495.pdf): Failed to open stream: HTTP request failed! HTTP/1.1 400 Bad Request
in /home/eprajournals-admin/htdocs/eprajournals.com/app/controllers/HomeController.php on line 84
Error fetching PDF file.